ACR Convergence 2025

October 24-29, 2025. Chicago, Illinois.

View by Number View by Title View Sessions

Monday, October 27, 2025

10:30AM-12:30PM: Abstract Number: 1010

Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review

(1007–1037) Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1478

Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1620

Correlation Between Histopathological Findings and PET-CT Results in Patients With Inflammatory Aortitis

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

10:30AM-12:30PM: Abstract Number: 1366

Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil

(1347–1375) Rheumatoid Arthritis – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0907

Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1207

Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis

(1191–1220) Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 1152

Cutaneous Panniculitis in Rheumatology: A Descriptive Cohort Study from a Multidisciplinary Experience

(1147–1190) Miscellaneous Rheumatic & Inflammatory Diseases Poster II

10:30AM-12:30PM: Abstract Number: 1599

Cyclophosphamide versus Rituximab in the treatment of Anca-associated Vasculitis: Adverse events and Relapses

(1592–1611) Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1390

Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome

(1376–1404) Sjögren’s Disease – Basic & Clinical Science Poster II: Clinical Manifestations and Health Outcomes

10:30AM-12:30PM: Abstract Number: 0901

Data-Driven Metabolomics Identifies Diagnostic Signatures and Patient Subgroups in Systemic Autoimmune Disorders

(0897–0915) B Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster II

10:30AM-12:30PM: Abstract Number: 1132

DDX3X Regulates Gout Inflammation via NLRP3 Inflammasome Activation and Macrophage Pyroptosis Crosstalk

(1123–1146) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

10:30AM-12:30PM: Abstract Number: 1311

Decade-Based Trends in First Remission Among Rheumatoid Arthritis Patients: A Population-Based Study

(1306–1346) Rheumatoid Arthritis – Diagnosis, Manifestations, and Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1484

Decoding the Impact of Systemic Lupus Erythematosus on Transcatheter Aortic Valve Implantation: A Nationwide population-based Study

(1467–1516) Systemic Lupus Erythematosus – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1567

Deep-learning analysis of HRCT images predicts progression and mortality in systemic sclerosis-related interstitial lung disease

(1553–1591) Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 1622

Defective CD4+ regulatory T cells in active Takayasu arteritis patients can be improved by efficiency treatment of tofacitinib

(1612–1632) Vasculitis – Non-ANCA-Associated & Related Disorders Poster II

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].